Cancer Research Cancer Epigenetics EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franconi, R.
Right arrow Articles by Giorgi, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franconi, R.
Right arrow Articles by Giorgi, C.
[Cancer Research 62, 3654-3658, July 1, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Plant-derived Human Papillomavirus 16 E7 Oncoprotein Induces Immune Response and Specific Tumor Protection1

Rosella Franconi, Paola Di Bonito, Francesco Dibello, Luisa Accardi, Antonio Muller, Alessia Cirilli, Paola Simeone, M. Gabriella Donà, Aldo Venuti2,,3 and Colomba Giorgi2,,3

Ente per le Nuove Tecnologie, Energia e Ambiente, UTS Biotech, Sezione Genetica e Genomica Vegetale, CR Casaccia [R. F., F. D.]; Istituto Superiore di Sanità Laboratory of Virology [P. D. B., F. D., L. A., M. G. D., C. G.]; and Cancer Institute "Regina Elena" [A. M., A. C., P. S., A. V.] Rome 00161, Italy

Vaccine strategies for treatment of human papillomavirus-induced cervical cancer are based on either the recombinant E7 fusion oncoprotein or E7 CTL peptides. The therapeutic potential of the E7-based vaccine depends on the use of different adjuvants.In this study, we describe for the first time the expression of the human papillomavirus 16 E7 protein in Nicotiana benthamiana plant using a potato virus X-derived vector. C57BL/6 mice immunized with E7-containing crude foliar extracts developed both humoral and cell-mediated immune responses and were protected from tumor development after challenge with the E7-expressing C3 tumoral cell line. Our data support the possibility of producing a cost-effective anticancer vaccine in plant with intrinsic adjuvant-like properties.




This article has been cited by other articles:


Home page
 CVIHome page
T. Kohl, I. I. Hitzeroth, D. Stewart, A. Varsani, V. A. Govan, N. D. Christensen, A.-L. Williamson, and E. P. Rybicki
Plant-Produced Cottontail Rabbit Papillomavirus L1 Protein Protects against Tumor Challenge: a Proof-of-Concept Study.
Clin. Vaccine Immunol., August 1, 2006; 13(8): 845 - 853.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Biemelt, U. Sonnewald, P. Galmbacher, L. Willmitzer, and M. Muller
Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic Plants
J. Virol., September 1, 2003; 77(17): 9211 - 9220.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.